Y-mAbs down as EU regulator recommends against cancer drug

Y-mAbs Therapeutics

16/12/2022 22:27

** Shares of Y-mAbs Therapeutics Inc  YMAB.O  fall 5% to
$4.75 after market 
    ** Company says EU's health regulator recommended against
the marketing authorization for its experimental cancer drug,
omburtamab, for treating a rare form of nerve cancer in
pediatric patients  urn:newsml:reuters.com:*:nGNXbdfLS8
    ** Regulator could not conclude on the effectiveness of
omburtamab as the main study did not have a randomized
comparator - company
    ** YMAB adds that is now accessing the implications of the
negative recommendation and its plans for omburtamab
    ** Earlier this month, U.S. FDA declined to approve the drug
    ** As of last close, stock was down ~69% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))